Why the study?
Does aspirin prevent postoperative venous thromboembolism in the POISE-2 trial population?
Does aspirin prevent postoperative venous thromboembolism in the POISE-2 trial population?
Answers are grounded in this paper and cite their sources.
This letter argues that the POISE-2 trial was underpowered to evaluate aspirin's efficacy in preventing postoperative VTE.
We read with interest the article by Eikelboom et al.1 reporting the results of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial regarding postoperative incidence of venous thromboembolism (VTE).We had several concerns:In conclusion, POISE-2 was underpowered to assess the ability of aspirin to prevent VTE. From the authors’ perspective, this major weakness was to be imputed to the low VTE rate. From ours, it stems from the insufficient sample size, for VTE rate was known a priori. Increasing sample size by pooling POISE-2 with PEP and APTC cannot fix this shortcoming due to different patient populations.The authors declare no competing interests.
No takes yet. Share an insight, caveat, or question.
Madi‐Jebara et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: